Irritable bowel syndrome
(IBS) was first mentioned as a concept in the
Rocky Mountain Medical Journal in 1950 and so is
a modern day epidemic. Recurrent abdominal pain
(RAP), an important feature of IBS, was first
described by Apley and Naish in 1958. Their
criteria were 3 episodes of abdominal pain over
3 months, severe enough to affect the daily
routine [1]. Irritable bowel syndrome (IBS), a
common subtype of RAP in children [2], is one of
the most common, non-infective gastrointestinal
(GI) disorders in the Western world but is now
increasingly recognized in adults in developing
countries [1,3]. IBS has now been defined under
the Rome III criteria as one of the functional
gastrointestinal disorders [4]. This article has
been written with the hope of stimulating
interest in the epidemiology and treatment of
IBS in children.
Definition
IBS is a subtype of RAP with
alteration of bowel habits (constipation,
diarrhea or alternating constipation and
diarrhea) [5]. IBS was defined by the current
Rome III criteria for functional
gastrointestinal disorders (FGIDs) including
IBS, abdominal migraine and functional abdominal
pain. For a clinical diagnosis of IBS the Rome
III criteria need to be fulfilled [4].
As the age ranges of children
seen in Pediatric practice varies in different
countries, the prevalence of IBS may vary
accordingly. Although the Rome III criteria
require report of abdominal pain by the child,
in practice younger children may present with
typical symptoms of IBS such as alternating
constipation and diarrhea with passage of mucus,
loose stools with distress after meals and
constipation with out of proportion distress,
relieved by defecation.
Etiology
The etiology of IBS remains
undetermined [1]. Infection, inflammation,
visceral hypersensitivity, allergy, or
disordered gut motility may play a part [3].
Genetic predisposition and stress are also
considered to compounding factors [3]. An
infectious trigger for IBS, (infectious
gastroenteritis more likely in developing
countries) may also play a role. In developed
countries, studies of bacterial gastrointestinal
infections in adults suggested that around 25%
continue to have longer lasting changes in bowel
habit following an episode and that a small
proportion develops IBS symptoms [6]. In a
postal questionnaire survey of 576 individuals
with a Salmonella or Campylobacter infection
(between 2000- 2009), nearly 10% of 189
individuals who responded to the questionnaire
reported post-infectious IBS symptoms up to 10
years later [7]. Similar findings were also
reported after an outbreak of gastroenteritis in
children which was found to be associated with
increased incidence of IBS [8].
A study in Norway showed that
7% of patients developed a post-infective FGID,
mostly IBS, after a large waterborne outbreak of
Giardia intestinalis infection [6, 9]. In
a prospective study of 102 children with
Giardia lamblia detected by ELISA in Russia,
the prevalence of IBS was found to be 28% in
girls and 17% in boys [10]. It is important to
specifically ask for stool ELISA or microscopy
for Giardia and treat with metronidazole
if detected before making a diagnosis of IBS
[10]. Hence continuing symptoms after treatment
of Giardiasis may reflect re-infection or the
development of IBS symptoms. The incidence of
post-infectious IBS in developing countries is
not known; this would allow for a better
description of risk factors for such children
with IBS [6]. In developing countries, abdominal
pain and diarrhea is often considered to be
infectious in origin and the chances of a
re-infection being high, pediatricians may not
consider IBS at the top of their differential
diagnosis. Moreover, IBS can have a waxing and
waning course leading to its late detection and
diagnosis [11].
There has been ongoing
interest in finding a genetic association in
IBS, more so because strong familial trends have
been seen. So far, a positive association
between IBS and an interleukin-10 polymorphism
has been reported. Interestingly, patients with
a mutation in a sodium channel gene (SCN5A)
have been found more often report
gastrointestinal symptoms, especially abdominal
pain and may be contributory factor in IBS
genetics [12]. Studies have also shown
associations between migraine and IBS and a
significant proportion of patients with IBS have
frequent headaches [2,13].
No direct co-relation between
IBS and malnutrition has been described.
However, it will not be surprising that children
with IBS may suffer from nutritional
deficiencies as post prandial abdominal pain may
make them apprehensive to eat which can make
their diet inadequate. It is therefore important
that any exclusion diet is discussed with a
dietician and adequate supplements are
prescribed.
Epidemiology
IBS is now increasingly being
recognized in younger children although majority
of patients are diagnosed in their adolescent
years [14,15]. In a community based study of 507
secondary school students in the USA who
reported abdominal pain (n=381), IBS type
symptoms were noted by 17% of high school and 8%
of middle school students [14,15]. Recent adult
studies have shown a lower range of prevalence
of IBS in Iran and India; i.e., 5.8% and 4.2%,
respectively; however, the values in other
developed Asian countries are possibly similar
to those seen in the Western countries [11,16].
Some questions therefore remain to be answered –
• Is there a significant
difference in the incidence of IBS in
developing and developed countries?
• Will the incidence of
IBS increase by adoption of a Western
lifestyle?
• Are predisposing
factors different in developing and
developed countries?
• Is the increasing
stress on young children to achieve or
family break-up responsible for IBS symptoms
becoming evident at a younger age?
The answer is probably ‘yes’
to a certain extent to all the questions. In the
absence of any other plausible explanation,
infective pathology is often considered the
trigger for the IBS, especially in developing
countries [6, 8].
Clinical Classification
The diagnosis of the various
FGIDs including IBS depends on a detailed
clinical history. Children with abdominal pain
and disordered bowel function are classified as
IBS, which may be associated with diarrhea
(IBSD), constipation (IBSC) or alternating
diarrhea and constipation (IBSA). Those with
epigastric pain are classified as functional
dyspepsia. Abdominal migraine causes
self-limiting episodes of severe abdominal pain
interspersed with periods of no pain. During
attacks of abdominal migraine, gastro-intestinal
symptoms may be associated. If severe vomiting
occurs at a regular interval interspersed with
symptom free periods in between, these children
are said to have cyclical vomiting syndrome [4].
The remaining children whose pattern of
abdominal pain does not fall into the above
groups are classified as functional abdominal
pain. If other symptoms such as headache and
limb pain are reported this is called functional
abdominal pain syndrome. Amongst the latter
group there are children with abdominal pain but
no gastro-intestinal symptoms whose pain is made
worse by exercise. Their pain is likely to be of
musculoskeletal in origin and may represent the
pediatric equivalent of adult abdominal wall
pain.
Diagnosis: Ruling out Other
Differential Diagnoses
The lack of definite
laboratory or radiological investigations to
diagnose IBS leads to a significant number of
referrals to the pediatricians and pediatric
gastroenterology services [5]. Diagnosing IBS
however remains a challenge for the clinicians.
A detailed history forms the most important
discriminator to confirm a clinical suspicion of
IBS. A family or personal history of cranial or
abdominal migraine can often be found in
association with IBS. Parents often describe
their child as a ‘little worrier’ and an anxiety
state is often present in association with IBS.
It is important to explore psychological issues
at school or home such as bullying, financial
difficulties, divorce or parental separation,
oncoming exams, etc. and these factors needs to
be addressed at the earliest for a successful
outcome in managing IBS symptoms. A history of
recent gastrointestinal infection may indicate a
starting point for IBS [6]. The Rome III
criteria should help the clinicians to make a
positive diagnosis of IBS and avoid unnecessary
surgery such as appendicectomy.
It is also important to ask
about (or elicit) red flag symptoms highlighted
in Box 1.
Box 1: Red Flags in Diagnosing IBS
•
Confirmed weight loss
•
Symptoms persistent or worse at night
(child wakes up with pain)
•
Unexplained anemia
•
Bleeding per rectum
•
Severe diarrhea and/or vomiting
•
Delayed puberty
•
Unexplained fever
• Strong family
history of inflammatory bowel disease
|
The diagnosis of IBS should
be made after exclusion of other organic causes
such as inflammatory bowel disease (IBD), celiac
disease, etc. As a minimum we suggest following
investigations to rule out organic pathologies:
serological screening for celiac disease,
inflammatory markers (ESR, CRP likely to be
raised in IBD), liver function tests (low
albumin in IBD), full blood count. Constipation
needs to be considered as it can present with
hard feces (constipation) and may be associated
with overflow spurious diarrhea mimicking
alternating constipation and diarrhea pattern
seen in IBSD. Especially in developing
countries, it is also important that a stool
sample is sent for microscopy and culture with
specific request to look for ova, cyst and
parasites (including Giardia). In the
absence of ‘red flags’ (Box 1) a
celiac screen will suffice in a Western
(country) clinical setting. An algorithm for
screening and rational investigations is
highlighted in Box 2.
Management
Once a diagnosis of IBS has
been agreed the next daunting task a clinician
faces is how best to manage the symptoms. The
aim for any therapeutic intervention in IBS is
to improve the quality of life, make the child
pain free and regulate the stool consistency and
frequency. The first step is to explain the
diagnosis, suggest strategies to cope with
stress, and reassure that there is nothing
seriously wrong [18].
The complex interplay of
biopsychosocial factors that may be involved in
the development of IBS in children highlights
the need for a multidisciplinary management
approach [18]. Before commencing an
intervention, the expected benefits of the
therapy need to be explained. Available
therapeutic interventions are as follows:
Placebo response:
There are only a few placebo controlled studies.
A recent multicentre double-blind, randomized
controlled trial (RCT) [19, 20] of low-dose
amitriptyline with placebo in treating children
with pain-related FGIDs for 4 weeks showed no
significant difference in the effectiveness of
amitriptyline and placebo therapy.
Another meta-analysis which
compared RCTs in children with IBS with no
treatment, placebo and active intervention
demonstrated that both spontaneous improvement
and the effect of placebo were instrumental in
contributing to the therapeutic effect observed
in the patients receiving active compounds [21].
Studies have also demonstrated that a strong
patient-clinician relationship is necessary and
the support provided along with positive
reinforcement provided by the clinician will
confer a successful placebo response [19].
Psychological interventions:
Many children with IBS receive psychological
interventions [22]. A Cochrane review which
included six trials conducted in children aged
between 5 to 18 years with RAP comparing
cognitive behavioral therapy (CBT) with standard
therapies such as dietary interventions,
pharmacological interventions, etc. concluded
that CBT may be a useful intervention for
children with RAP and IBS [22]. However, the
evidence remains weak and bigger RCTs are
necessary to establish this as a standard
therapeutic intervention.
Some studies have shown that
hypnotherapy may produce a beneficial effect in
children with IBS for at least five years. It is
believed that hypnotherapy normalizes altered
visceral sensation, reduces colonic phasic
contractions and reverses the patients’ negative
thoughts about their condition. A recent
systemic review found that all trials
demonstrated statistically significant
improvement in abdominal pain scores in children
in hypnotherapy group [23]. The authors
recommended hypnotherapy as the first line in
the management of children with IBS [23].
Behavioral therapies are beset by unavailability
of therapists and the need for a number of
sessions.
Pharmacological interventions:
There is a weak evidence that pharmacological
agents may provide relief from symptoms [24].
Functional abdominal pain and IBS are considered
to be a state of dysregulation within the
enteric and the central nervous systems,
resulting in alterations in sensation, motility,
and possibly, immune system function.
Pharmacological interventions for FGIDs should
therefore be based on the understanding of
bidirectional brain gut interactions, the
‘‘brain-gut axis.’’ [25].
Antispasmodic agents can be
used when diarrhea is the predominant symptom in
IBS to attenuate heightened baseline and
postprandial contractility [26]. Mebeverine is
licensed in the UK and is generally well
tolerated; and can be used on an as required
basis before meals. Other classes of
antispasmodic such as calcium channel blockers
have not shown any consistent benefit in IBS and
are licensed for children in only a few
countries [27]. In a recent study clinical
recovery was seen in 94.9% of children treated
with trimebutine maleate at the end of 3 weeks
when compared to the non-medicated group where
spontaneous recovery was seen in only 20.5%
children [28]. Children in this study
predominantly had IBS with constipation.
Antidepressants have shown
some benefit in treating children with IBS
symptoms [15,20]. In a study of 98 children who
took amitriptyline for FGID; 77 patients
responded to the treatment for an average of
10.7 months and this effectiveness persisted
[29]. Selective Serotonin Reuptake Inhibitors
(SSRIs) are widely used for treating anxiety,
depression, and somatization disorders. Four
RCTs of SSRIs in IBS showed that a standard dose
of an SSRI led to a significant improvement in
health related quality of life in patients
(adults) with chronic or treatment resistant
IBS.
Fiber, including bran,
ispaghula husk, methylcellulose and sterculia,
is sometimes used in children with constipation
predominant IBS. However, only 10% of patients
are improved by such agents, and insoluble fiber
has been shown in a placebo controlled RCT to
have no effect on pain and to exacerbate
flatulence and bloating [30]. The traditional
use of a high fibre diet may not be well
tolerated by children [18,31].
Stimulant laxatives are
associated with increased abdominal pain and
tachyphylaxis [32]. If a long term treatment is
considered necessary, polyethylene glycol (PEG)
based laxative therapy may be a better option
for treating IBSC [32].
Anti-diarrheal agents have a
limited role and may be tried in children with
diarrhea predominant IBS symptoms (IBSD).
Loperamide, an opiate analogue, acts by
stimulating inhibitory presynaptic receptors in
the enteric nervous system resulting in
inhibition of peristalsis and intestinal
secretion. Studies in adults have found
loperamide to be effective in reducing diarrhea
in IBS patients but not symptoms of abdominal
pain [33].
Serotonin (5-HT) acts through
the 5-HT3 and 5-HT4 receptors and plays a
significant role in the control of
gastrointestinal motility, sensation, and
secretion. Recent observations suggest that
plasma 5-HT concentrations are reduced in IBS
patients with constipation, but are raised in
those with diarrhea, especially those showing
postprandial symptoms. This has led to a
considerable interest in these receptors as
possible therapeutic targets for IBS. The 5-HT4
receptor agonists are predicted to enhance
gastrointestinal propulsion and will be helpful
in constipation predominant IBS. The antagonists
at the 5-HT3 receptor slows gastrointestinal
transit and reduce visceral sensation; this
should be useful in diarrhea predominant IBS.
If pharmacological treatment
is considered, in a chronic condition such as
IBS, the drug should be withdrawn periodically
to determine whether it is still required.
Intermittent treatment at times of stress can be
effective.
Antibiotics: The role
of antibiotics as a treatment remains
controversial. While it is true that infectious
gastroenteritis are known to trigger IBS
symptoms and often clinicians choose to use
antibiotics as a trial to see if it would help
ruling out a treatable cause, especially in
developing countries. However, it should be
noted that IBS is less commonly reported from
developing countries and it is possible that
there may be reluctance amongst the clinicians
to diagnose IBS. In an adult study (aged
³18
years), encouraging results in symptoms were
noted in IBS patients treated with Rifaximin for
at least 2 weeks [34]. In a study of 43 children
with IBS symptoms, whose Visual Analogue Scale
(VAS) score to evaluate symptoms (abdominal
pain, constipation, diarrhea, bloating,
flatulence) showed improvement after 1 month
treatment with 600 mg of Rifaximin [35]. The
rationale behind this treatment is to eradicate
small intestinal bacterial overgrowth [34,35].
An alternative and safer approach is to use
probiotics rather than antibiotics.
Dietary interventions:
These form an important strategy in managing
children with IBS. Wherever available a
pediatric dietician should be involved when such
interventions are considered.
A recent Cochrane review [36]
considered seven trials: two trials compared
fiber supplements with placebo; two trials
studied a lactose-free diet in comparison to
placebo, and three trials compared supplements
of lactic acid producing bacteria with placebo.
The authors concluded that there is a lack of
high quality evidence on the effectiveness of
dietary interventions.
In a study, 59 children (4 to
18 years) were randomized to receive either a
probiotic or a placebo for 6 weeks [5],
probiotic was superior to placebo both in
primary (subjective assessment of relief of
symptoms) and secondary endpoints (abdominal
pain/discomfort, abdominal bloating/gassiness
and family assessment of life disruption).
Lactobacillus reuteri has also been
effective in relieving functional abdominal pain
compared with placebo [37]. Other RCTs have also
shown encouraging results with probiotics [38].
In an observational study
involving 46 children (1 to 18 years) with IBS
treated with partially hydrolyzed guar gum (Optifibre
Nestlé) for a period of 6 to 8 weeks [31], 82%
patients showed improvement in their alternating
constipation and diarrhea and (58% showed
improvement in their diarrhea only symptoms. In
the same study group, 68% also showed
significant improvement in their abdominal pain.
Similar beneficial findings were replicated in a
recent RCT from Italy involving 60 children
(8-16 y) with IBS and RAP being treated with
PHGG with statistically significant results
showing tendency toward normalization of bowel
movements in IBS subgroups [39].
Parents generally accept
dietary treatment more willingly than drugs. In
our practice we try long chain fatty acid
supplementation (Calogen Nutricia) to slow
intestinal transit for IBSD, PHGG for IBSA and
PEG-based laxative for IBSC. If this is
unsuccessful we try probiotic supplement (Li
reuteri) [37] or dairy free diet. If
symptoms persist, drugs (Merbentyl, Peppermint
oil) are tried [24]. In selected cases we have
used gut-focused hypnotherapy with encouraging
results.
The Indian scenario
An infective trigger may
often be the starting point of IBS symptoms.
With the ever increasing challenge to achieve
and the associated stress, IBS is more often
likely to be seen in Indian children than ever
before. It is also important that more emphasis
is given towards making a clinical diagnosis of
IBS due to the limited availability of resources
and the economic viability of conducting often
unnecessary laboratory and radiological
investigations.
The management of IBS remains
a challenge worldwide with no clear consensus
available, this will make it even more
challenging in the context of a developing
country like India where psychological or
dietary interventions may only be available in
tertiary centres. The management will be largely
dependent on the physician and it is of
paramount importance that a trusting
relationship is developed with the
patient/family to ensure success of any intended
therapy.
The first step should always
be an explanation and reassurance unless the
symptoms are very severe at the initial
presentation. Where there is a clear history of
an infective trigger and diarrhea-predominant
IBS symptoms, it may be appropriate to consider
the presence of small intestinal bacterial
overgrowth. While an abnormal bowel flora may
occur in IBS, in the absence of more data the
use broad spectrum antibiotics is expensive,
increases antibiotic resistance and puts the
child at risk of antibiotic associated diarrhea.
Some amount of psychological
counseling can be provided by the clinician and
the knowledge that there is nothing seriously
wrong in the child often works wonders. Other
stressful triggers in school and home may be
easily addressed if the parents feel confident
about the diagnosis and make adjustments to the
child’s lifestyle. Pharmacological and to a
certain extent dietary adjustments can be tried
even in the absence of a specialist dietician;
however, where such services are available the
management should include a multi-disciplinary
team including dieticians and clinical
psychologists.
In the absence of
evidence-based data, any conclusions on the
dietary and lifestyle management of IBS in the
Indian Subcontinent must be speculative.
However, the traditional Indian food often
contains vegetable oil, ghee, etc. and this may
have a beneficial effect in children with IBS as
these food items consists of a significant
proportion of long-chain fatty acid.
Treatment of IBSD and IBSA
based on partially hydrolyzed guar gum, which is
naturally occurring and other soluble fibers may
be effective [31].
Hypnotherapy could be
mirrored by meditation, yoga and chanting [40].
Yoga exercises were found to be effective in
significantly reducing abdominal pain in
children with IBS and this persisted after 3
months of completion of therapy [40].
Conclusions
IBS often presents a clinical
challenge because of the nature of the symptoms
and its interpretation amongst parents and
physicians. A detailed focused history will
clarify lot of uncertainties about the symptoms
and investigations should be kept to the minimum
and aimed at ruling out other serious
pathologies. Successful management of IBS in
children revolves around time spent at
explaining and reassuring the child and the
parents. Where a treatment is contemplated it is
important that the expected benefits and
possible side-effects are explained to the
family before commencing on the therapy.
Whenever available and feasible the aim should
be to involve a multi-disciplinary team in
managing children with IBS.
Contributors: All the
authors have contributed to the manuscript.
Funding: None;
Competing interests: None stated.
References
1. Bremner AR, Sandhu BK.
Recurrent abdominal pain in childhood: The
functional element. Indian Pediatr.
2009;46:375-9.
2. El-Matary W, Spray C,
Sandhu B. Irritable bowel syndrome: the
commonest cause of recurrent abdominal pain in
children. Eur J Pediatr. 2004;163:584-8.
3. Muller-Lissner S, Kock G,
Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf
C, et al. Subject’s global assessment of
relief: an appropriate method to assess the
impact of treatment on irritable bowel
syndrome-related symptoms in clinical trials. J
Clin Epidemiol. 2003:56:310-6.
4. Rasquin A, Di Lorenzo C,
Forbes D, Guiraldes E, Hyams J, Staiano A, et
al. Childhood functional gastrointestinal
disorders. Gastroenterology 2006;130: 1527-37.
5. Guandalini S, Magazzu‘ G,
Chiaro A, La Balestra V, Di Nardo G, Gopalan S,
et al. VSL#3 Improves symptoms in
children with irritable bowel syndrome: A
multicenter, eandomized, placebo-controlled,
double-blind, crossover study. J Pediatr
Gastroenterol Nutr. 2010;51: 24–30.
6. Spiller R, Garsed K.
Infection, inflammation, and the irritable bowel
syndrome. Dig Liver Dis. 2009;41:844-9.
7. Schwille-Kiuntke J, Enck
P, Zendler C, Krieg M, Polster AV, Klosterhalfen
S, et al. Postinfectious irritable bowel
syndrome: follow-up of a patient cohort of
confirmed cases of bacterial infection with
Salmonella or Campy-lobacter.
Neurogastroenterol Motil. 2011;23:e479-88.
8. Thabane M, Simunovic M,
Akhtar-Danesh N, Garg AX, Clark WF, Collins SM,
et al. An outbreak of acute bacterial
gastroenteritis is associated with an increased
incidence of irritable bowel syndrome in
children. Am J Gastroenterol. 2010;105:933-9.
9. Dizdar V, Gilja OH,
Hausken T. Increased visceral sensitivity in
Giardia-induced postinfectious irritable
bowel syndrome and functional dyspepsia. Effect
of the 5HT3-antagonist ondansetron.
Neurogastroenterol Motil. 2007;19:977–82.
10. Guzyeyeva GV. Giardia
lamblia infection in hospitalized children
with irritable bowel syndrome and dyspepsia: a
prospective study. Faseb J. 2009;980.5
(Abstract).
11. Ghoshal UC, Abraham P,
Bhatt C, Choudhuri G, Bhatia SJ, Shenoy KT,
et al. Epidemiological and clinical profile
of irritable bowel syndrome in India: report of
the Indian Society of Gastroenterology Task
Force. Indian J Gastroenterol. 2008;27:22-8.
12. Talley NJ. Genetics and
Functional bowel disease. J Pediatr
Gastroenterol Nutr. 2008; 47:680-2.
13. Mulak A, Paradowski L.
Migraine and irritable bowel syndrome. Neurol
Neurochir Pol. 2005;39:S55-60.
14. Hyams JS, Burke G, Davis
PM, Rzepski B, Andrulonis PA. Abdominal pain and
irritable bowel syndrome in adolescents: a
community-based study. J Pediatr.
1996;129:220-6.
15. Bahar RJ, Collins BS,
Steinmetz B, Ament ME. Double-blind
placebo-controlled trial of amitriptyline for
the treatment of irritable bowel syndrome in
adolescents. J Pediatr. 2008;152:685-9.
16. Hoseini-Asl MK, Amra B.
Prevalence of irritable bowel syndrome in
Shahrekord, Iran. Indian J Gastroenterol.
2003;22:215-6.
17. Candy DCA, Edwards E. The
management of chronic constipation. Curr Pediatr.
2003;13: 101-6.
18. Chiou E, Nurko S.
Management of functional abdominal pain and
irritable bowel syndrome in children and
adolescents. Expert Rev Gastroenterol Hepatol.
2010;4:293–304.
19. Benniga MA, Mayer EA. The
Power of Placebo in Pediatric Functional
Gastrointestinal Disease. Gastroenterology.
2009;137:1207-10.
20. Saps M, Youssef N,
Miranda A, Nurko S, Hyman P, Cocjin J, et al.
Multicenter, randomized placebo-controlled trial
of amitriptyline in children with functional
gastrointestinal disorders. Gastroenterology.
2009;137:1261-9.
21. Krogsbøll LT,
Hróbjartsson A, Gøtzsche PC. Spontaneous
improvement in randomised clinical trials:
meta-analysis of three armed trials comparing no
treatment, placebo and active intervention. BMC
Med Res Methodol. 2009;9:1.
22. Huertas-Ceballos AA,
Logan S, Bennett C, Macarthur C. Psychosocial
interventions for recurrent abdominal pain(RAP)
and irritable bowel syndrome (IBS) in childhood.
Cochrane Database of Systematic Reviews
2008, Issue 1. Art. No.: CD003014.
23. Rutten JM, Reitsma JB,
Vlieger AM, Vlieger AM, Benniga MA. Gut-directed
hypnotherapy for functional abdominal pain or
irritable bowel syndrome in children: a
systematic review. Arch Dis Child. 2013;
98:252–7.
24. Huertas-Ceballos AA,
Logan S, Bennett C, Macarthur C. Pharmacological
interventions for recurrent abdominal pain(RAP)
and irritable bowel syndrome (IBS) in childhood.
Cochrane Database of Systematic Reviews
2008, Issue 1. Art. No.: CD003017.
25. Lebel AA. Pharmacology. J
Pediatr Gastroenterol Nutr. 2008;47:703-5.
26. Chey WY, Jin HO, Lee MH,
Sun SW, Lee KY. Colonic motility abnormality in
patients with irritable bowel syndrome
exhibiting abdominal pain and diarrhea. Am J
Gastroenterol. 2001;96:1499-506.
27. Awad R, Dibildox M, Ortiz
F. Irritable bowel syndrome treatment using
pinaverium bromide as a calcium channel blocker.
A randomized double-blind placebo-controlled
trial. Acta Gastroenterol Latinoam.
1995;25:137-44.
28. Karabulut GS, Beºer OF,
Erginöz E, Kutlu T, Cokuðraþ FÇ, Erkan T. The
incidence of irritable bowel syndrome in
children using the Rome III Criteria and the
effect of trimebutine treatment. J
Neurogastroenterol Motil. 2013;19:90-3.
29. Teitelbaum JE, Arora R.
Long-term efficacy of low-dose tricyclic
antidepressants for children with functional
gastrointestinal disorders. J Pediatr
Gastroenterol Nutr. 2011;53:260-4.
30. Snook J, Shepherd HA.
Bran supplementation in the treatment of
irritable bowel syndrome. Aliment Pharmacol Ther.
1994;8:511-4.
31. Paul SP, Barnard P, Edate
S, Candy DC. Stool consistency and abdominal
pain in irritable bowel syndrome may be improved
by partially hydrolysed guar gum. J Pediatr
Gastroenterol Nutr. 2011;53:582-3.
32. NICE CG99. Diagnosis and
management of idiopathic childhood constipation
in primary and secondary care.
http://www.nice.org.uk/nicemedia/live/12993/48721/48721.pdf.
33. Cann PA, Read NW,
Holdsworth CD, Barends D. Role of loperamide and
placebo in management of irritable bowel
syndrome (IBS). Dig Dis Sci. 1984;29:239-47.
34. Pimentel M, Lembo A, Chey
WD, Zakko S, Ringel Y, Yu J, et al.
Rifaximin therapy for patients with irritable
bowel syndrome without constipation. N Engl J
Med. 2011;364:22-32.
35. Giorgio V, D’ Andrea V,
Coccia P, Filoni S, Rendeli C, Fundarò C.
Efficacy of rifaximin for SIBO treatment in IBS
children. Pediatr. Res. 2010;68,144.
36. Huertas-Ceballos AA,
Logan S, Bennett C, Macarthur C. Dietary
interventions for recurrent abdominal pain (RAP)
and irritable bowel syndrome (IBS) in childhood.
Cochrane Database of Systematic Reviews
2009, Issue 1. Art. No.: CD003019.
37. Romano C, Ferrau V,
Cavataio F, Iacono G, Spina M, Lionetti E, et
al. Lactobacillus reuteri in children
with functional abdominal pain (FAP). J Paediatr
Child Health. 2010.Jul8. (Epub ahead of print).
38. Chen CC, Walker WA.
Clinical applications of probiotics in
gastrointestinal disorders in children. Natl Med
J India. 2011;24:153-60.
39. Romano C, Comito D,
Famini A, Calamarà S, Loddo I. Partially
hydrolyzed guar gum in pediatric functional
abdominal pain. World J Gastroenterol.
2013;19:235-40.
40. Brands MM, Purperhart H,
Deckers-Kocken JM. A pilot study of yoga
treatment in children with functional abdominal
pain and irritable bowel syndrome. Complement
Ther Med. 2011;19:109-14.